This week’s newsletter covers the uncertain fate of cannabis rescheduling under the Trump administration, along with new research on psychedelic polypharmacy, psilocybin’s role in fear extinction and cancer-related depression, and the psychological aftermath of intense psychedelic experiences.
Noteworthy Read
DOJ Could Ignore Trump’s Marijuana Rescheduling Directive, Congressional Researchers Suggest (Marijuana Moment)
A new report notes that although President Trump signed an executive order directing the attorney general to complete the process of moving marijuana from Schedule I to Schedule III, the Justice Department hasn’t finalized rescheduling yet and could, in theory, choose to restart the review or delay action—leaving rescheduling unresolved for the time being.
Read the article
View more in CBD
More Noteworthy Reading
The Polypharmacy of Psychedelics Reveals Multiple Targets for Potential Therapeutics (Neuron)
A new Neuron research article reviews how combining psychedelics with other drugs (polypharmacy) can engage multiple neural targets and signaling pathways, pointing to potential therapeutic strategies beyond single-compound effects.
Read more
View more in Drug Interactions
Psilocybin Helps the Brain Unlearn Fear by Silencing Specific Neural Pathways (PsyPost)
A study reports that psilocybin facilitates fear extinction by suppressing activity in neural circuits linked to threat memory, offering insight into how the compound may help treat PTSD and anxiety disorders.
Read more
View more in Psychedelics
Navigating Groundlessness: Dealing With Ontological Shock and Existential Distress Following Psychedelic Experiences (PLOS ONE)
Researchers surveyed individuals who had intense psychedelic experiences and found that some reported “ontological shock” or existential distress afterward; the study discusses how to mitigate potential long-term negative impacts.
Read more
View more in Psychedelics
Research Round-Up
Psilocybin Shows Promise for Rapid Reduction of Cancer-Related Depression (PsyPost)
Early clinical findings suggest that psilocybin therapy may sharply reduce depressive symptoms in cancer patients within days, underscoring its potential as a fast-acting treatment for existential distress and mood disorders tied to serious illness.
Read more
View more in Psychedelics
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to shine a light on the latest plant medicine research and bring these important stories to our readers.
Be the first to comment